Table 2.

Subgroup analysis for the absence of fluid, interval extension and retention rate

	12 months				24 months
	n	kS	%	p	n	kS	%	p
Absence of fluid
Ranibizumab 0.5 mg	1062	7	56.3	< 0.001	1081	5	50.0	< 0.001
Aflibercept 2.0 mg	442	5	64.5		1938	9	52.7
Brolucizumab 6.0 mg	730	2	71.5		646	2	75.7
Interval extension (12 weeks)
Ranibizumab 0.5 mg	943	6	28.6	< 0.001	1339	7	34.2	< 0.001
Aflibercept 2.0 mg	770	7	34.2		2360	13	47.7
Brolucizumab 6.0 mg	730	2	53.3		646	2	41.7
Retention rate
Ranibizumab 0.5 mg	943	6	90.5	0.69	1339	7	81.6	< 0.001
Aflibercept 2.0 mg	60	2	91.0		2266	12	81.7
Brolucizumab 6.0 mg	730	2	91.6		646	2	88.6

k_S, number of samples included in the analysis

The p value represents the difference between all three groups